Global Immune Thrombocytopenic Purpura Therapeutics Market Research Report 2024

Report ID: 1977423 | Published Date: Jan 2025 | No. of Page: 91 | Base Year: 2024 | Rating: 4.1 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Eltrombopag Olamine
        1.2.3 Fostamatinib Disodium
        1.2.4 GL-2045
        1.2.5 Avatrombopag
        1.2.6 BI-655064
        1.2.7 Others
    1.3 Market by Application
        1.3.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered
2 Global Growth Trends
    2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Perspective (2018-2029)
    2.2 Immune Thrombocytopenic Purpura Therapeutics Growth Trends by Region
        2.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Immune Thrombocytopenic Purpura Therapeutics Historic Market Size by Region (2018-2023)
        2.2.3 Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Region (2024-2029)
    2.3 Immune Thrombocytopenic Purpura Therapeutics Market Dynamics
        2.3.1 Immune Thrombocytopenic Purpura Therapeutics Industry Trends
        2.3.2 Immune Thrombocytopenic Purpura Therapeutics Market Drivers
        2.3.3 Immune Thrombocytopenic Purpura Therapeutics Market Challenges
        2.3.4 Immune Thrombocytopenic Purpura Therapeutics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Revenue
        3.1.1 Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Revenue (2018-2023)
        3.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Players (2018-2023)
    3.2 Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Immune Thrombocytopenic Purpura Therapeutics Revenue
    3.4 Global Immune Thrombocytopenic Purpura Therapeutics Market Concentration Ratio
        3.4.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Immune Thrombocytopenic Purpura Therapeutics Revenue in 2022
    3.5 Immune Thrombocytopenic Purpura Therapeutics Key Players Head office and Area Served
    3.6 Key Players Immune Thrombocytopenic Purpura Therapeutics Product Solution and Service
    3.7 Date of Enter into Immune Thrombocytopenic Purpura Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Immune Thrombocytopenic Purpura Therapeutics Breakdown Data by Type
    4.1 Global Immune Thrombocytopenic Purpura Therapeutics Historic Market Size by Type (2018-2023)
    4.2 Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Type (2024-2029)
5 Immune Thrombocytopenic Purpura Therapeutics Breakdown Data by Application
    5.1 Global Immune Thrombocytopenic Purpura Therapeutics Historic Market Size by Application (2018-2023)
    5.2 Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
    6.1 North America Immune Thrombocytopenic Purpura Therapeutics Market Size (2018-2029)
    6.2 North America Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2018-2023)
    6.4 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada
7 Europe
    7.1 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size (2018-2029)
    7.2 Europe Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2018-2023)
    7.4 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size (2018-2029)
    8.2 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2018-2023)
    8.4 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia
9 Latin America
    9.1 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size (2018-2029)
    9.2 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2018-2023)
    9.4 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size (2018-2029)
    10.2 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2018-2023)
    10.4 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE
11 Key Players Profiles
    11.1 Amgen Inc.
        11.1.1 Amgen Inc. Company Detail
        11.1.2 Amgen Inc. Business Overview
        11.1.3 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.1.4 Amgen Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.1.5 Amgen Inc. Recent Development
    11.2 Baxalta Incorporated
        11.2.1 Baxalta Incorporated Company Detail
        11.2.2 Baxalta Incorporated Business Overview
        11.2.3 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.2.4 Baxalta Incorporated Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.2.5 Baxalta Incorporated Recent Development
    11.3 Boehringer Ingelheim GmbH
        11.3.1 Boehringer Ingelheim GmbH Company Detail
        11.3.2 Boehringer Ingelheim GmbH Business Overview
        11.3.3 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.3.4 Boehringer Ingelheim GmbH Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.3.5 Boehringer Ingelheim GmbH Recent Development
    11.4 Bristol-Myers Squibb Company
        11.4.1 Bristol-Myers Squibb Company Company Detail
        11.4.2 Bristol-Myers Squibb Company Business Overview
        11.4.3 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.4.4 Bristol-Myers Squibb Company Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.4.5 Bristol-Myers Squibb Company Recent Development
    11.5 Eisai
        11.5.1 Eisai Company Detail
        11.5.2 Eisai Business Overview
        11.5.3 Eisai Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.5.4 Eisai Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.5.5 Eisai Recent Development
    11.6 Hansa Medical AB
        11.6.1 Hansa Medical AB Company Detail
        11.6.2 Hansa Medical AB Business Overview
        11.6.3 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.6.4 Hansa Medical AB Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.6.5 Hansa Medical AB Recent Development
    11.7 Immunomedics, Inc.
        11.7.1 Immunomedics, Inc. Company Detail
        11.7.2 Immunomedics, Inc. Business Overview
        11.7.3 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.7.4 Immunomedics, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.7.5 Immunomedics, Inc. Recent Development
    11.8 Intas Pharmaceuticals Ltd.
        11.8.1 Intas Pharmaceuticals Ltd. Company Detail
        11.8.2 Intas Pharmaceuticals Ltd. Business Overview
        11.8.3 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.8.4 Intas Pharmaceuticals Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.8.5 Intas Pharmaceuticals Ltd. Recent Development
    11.9 Jiangsu Hengrui Medicine Co., Ltd.
        11.9.1 Jiangsu Hengrui Medicine Co., Ltd. Company Detail
        11.9.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
        11.9.3 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.9.4 Jiangsu Hengrui Medicine Co., Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.9.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
    11.10 Merck & Co., Inc.
        11.10.1 Merck & Co., Inc. Company Detail
        11.10.2 Merck & Co., Inc. Business Overview
        11.10.3 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.10.4 Merck & Co., Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.10.5 Merck & Co., Inc. Recent Development
    11.11 Momenta Pharmaceuticals, Inc.
        11.11.1 Momenta Pharmaceuticals, Inc. Company Detail
        11.11.2 Momenta Pharmaceuticals, Inc. Business Overview
        11.11.3 Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.11.4 Momenta Pharmaceuticals, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.11.5 Momenta Pharmaceuticals, Inc. Recent Development
    11.12 Novartis AG
        11.12.1 Novartis AG Company Detail
        11.12.2 Novartis AG Business Overview
        11.12.3 Novartis AG Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.12.4 Novartis AG Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.12.5 Novartis AG Recent Development
    11.13 Pfizer Inc.
        11.13.1 Pfizer Inc. Company Detail
        11.13.2 Pfizer Inc. Business Overview
        11.13.3 Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
        11.13.4 Pfizer Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
        11.13.5 Pfizer Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Eltrombopag Olamine
    Table 3. Key Players of Fostamatinib Disodium
    Table 4. Key Players of GL-2045
    Table 5. Key Players of Avatrombopag
    Table 6. Key Players of BI-655064
    Table 7. Key Players of Others
    Table 8. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 9. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 10. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 11. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Region (2018-2023)
    Table 12. Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 13. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Region (2024-2029)
    Table 14. Immune Thrombocytopenic Purpura Therapeutics Market Trends
    Table 15. Immune Thrombocytopenic Purpura Therapeutics Market Drivers
    Table 16. Immune Thrombocytopenic Purpura Therapeutics Market Challenges
    Table 17. Immune Thrombocytopenic Purpura Therapeutics Market Restraints
    Table 18. Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Players (2018-2023) & (US$ Million)
    Table 19. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Players (2018-2023)
    Table 20. Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenic Purpura Therapeutics as of 2022)
    Table 21. Ranking of Global Top Immune Thrombocytopenic Purpura Therapeutics Companies by Revenue (US$ Million) in 2022
    Table 22. Global 5 Largest Players Market Share by Immune Thrombocytopenic Purpura Therapeutics Revenue (CR5 and HHI) & (2018-2023)
    Table 23. Key Players Headquarters and Area Served
    Table 24. Key Players Immune Thrombocytopenic Purpura Therapeutics Product Solution and Service
    Table 25. Date of Enter into Immune Thrombocytopenic Purpura Therapeutics Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 28. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2018-2023)
    Table 29. Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 30. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2024-2029)
    Table 31. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 32. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Application (2018-2023)
    Table 33. Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 34. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Application (2024-2029)
    Table 35. North America Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 36. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 37. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 38. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 39. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 40. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 41. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 42. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 43. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2024-2029) & (US$ Million)
    Table 44. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 45. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 46. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 47. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 48. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 50. Amgen Inc. Company Detail
    Table 51. Amgen Inc. Business Overview
    Table 52. Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Product
    Table 53. Amgen Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 54. Amgen Inc. Recent Development
    Table 55. Baxalta Incorporated Company Detail
    Table 56. Baxalta Incorporated Business Overview
    Table 57. Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Product
    Table 58. Baxalta Incorporated Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 59. Baxalta Incorporated Recent Development
    Table 60. Boehringer Ingelheim GmbH Company Detail
    Table 61. Boehringer Ingelheim GmbH Business Overview
    Table 62. Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Product
    Table 63. Boehringer Ingelheim GmbH Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 64. Boehringer Ingelheim GmbH Recent Development
    Table 65. Bristol-Myers Squibb Company Company Detail
    Table 66. Bristol-Myers Squibb Company Business Overview
    Table 67. Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Product
    Table 68. Bristol-Myers Squibb Company Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 69. Bristol-Myers Squibb Company Recent Development
    Table 70. Eisai Company Detail
    Table 71. Eisai Business Overview
    Table 72. Eisai Immune Thrombocytopenic Purpura Therapeutics Product
    Table 73. Eisai Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 74. Eisai Recent Development
    Table 75. Hansa Medical AB Company Detail
    Table 76. Hansa Medical AB Business Overview
    Table 77. Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Product
    Table 78. Hansa Medical AB Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 79. Hansa Medical AB Recent Development
    Table 80. Immunomedics, Inc. Company Detail
    Table 81. Immunomedics, Inc. Business Overview
    Table 82. Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Product
    Table 83. Immunomedics, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 84. Immunomedics, Inc. Recent Development
    Table 85. Intas Pharmaceuticals Ltd. Company Detail
    Table 86. Intas Pharmaceuticals Ltd. Business Overview
    Table 87. Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Product
    Table 88. Intas Pharmaceuticals Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 89. Intas Pharmaceuticals Ltd. Recent Development
    Table 90. Jiangsu Hengrui Medicine Co., Ltd. Company Detail
    Table 91. Jiangsu Hengrui Medicine Co., Ltd. Business Overview
    Table 92. Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Product
    Table 93. Jiangsu Hengrui Medicine Co., Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 94. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
    Table 95. Merck & Co., Inc. Company Detail
    Table 96. Merck & Co., Inc. Business Overview
    Table 97. Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Product
    Table 98. Merck & Co., Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 99. Merck & Co., Inc. Recent Development
    Table 100. Momenta Pharmaceuticals, Inc. Company Detail
    Table 101. Momenta Pharmaceuticals, Inc. Business Overview
    Table 102. Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Product
    Table 103. Momenta Pharmaceuticals, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 104. Momenta Pharmaceuticals, Inc. Recent Development
    Table 105. Novartis AG Company Detail
    Table 106. Novartis AG Business Overview
    Table 107. Novartis AG Immune Thrombocytopenic Purpura Therapeutics Product
    Table 108. Novartis AG Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 109. Novartis AG Recent Development
    Table 110. Pfizer Inc. Company Detail
    Table 111. Pfizer Inc. Business Overview
    Table 112. Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Product
    Table 113. Pfizer Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023) & (US$ Million)
    Table 114. Pfizer Inc. Recent Development
    Table 115. Research Programs/Design for This Report
    Table 116. Key Data Information from Secondary Sources
    Table 117. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Type: 2022 VS 2029
    Figure 3. Eltrombopag Olamine Features
    Figure 4. Fostamatinib Disodium Features
    Figure 5. GL-2045 Features
    Figure 6. Avatrombopag Features
    Figure 7. BI-655064 Features
    Figure 8. Others Features
    Figure 9. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 10. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Application: 2022 VS 2029
    Figure 11. Hospital Case Studies
    Figure 12. Clinic Case Studies
    Figure 13. Others Case Studies
    Figure 14. Immune Thrombocytopenic Purpura Therapeutics Report Years Considered
    Figure 15. Global Immune Thrombocytopenic Purpura Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 16. Global Immune Thrombocytopenic Purpura Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 17. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Region: 2022 VS 2029
    Figure 18. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Players in 2022
    Figure 19. Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenic Purpura Therapeutics as of 2022)
    Figure 20. The Top 10 and 5 Players Market Share by Immune Thrombocytopenic Purpura Therapeutics Revenue in 2022
    Figure 21. North America Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 22. North America Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2018-2029)
    Figure 23. United States Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. Canada Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. Europe Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2018-2029)
    Figure 27. Germany Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. France Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. U.K. Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Italy Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Russia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Nordic Countries Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Share by Region (2018-2029)
    Figure 35. China Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. Japan Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. South Korea Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. Southeast Asia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. India Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. Australia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2018-2029)
    Figure 43. Mexico Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Brazil Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2018-2029)
    Figure 47. Turkey Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 48. Saudi Arabia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 49. Amgen Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 50. Baxalta Incorporated Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 51. Boehringer Ingelheim GmbH Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 52. Bristol-Myers Squibb Company Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 53. Eisai Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 54. Hansa Medical AB Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 55. Immunomedics, Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 56. Intas Pharmaceuticals Ltd. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 57. Jiangsu Hengrui Medicine Co., Ltd. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 58. Merck & Co., Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 59. Momenta Pharmaceuticals, Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 60. Novartis AG Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 61. Pfizer Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2018-2023)
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Amgen Inc.
Baxalta Incorporated
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eisai
Hansa Medical AB
Immunomedics, Inc.
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
Frequently Asked Questions
Immune Thrombocytopenic Purpura Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Immune Thrombocytopenic Purpura Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Immune Thrombocytopenic Purpura Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports